Our site uses cookies. Learn more about our use of cookies: cookie policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to content Skip to footer
Subscribe Now
News

Boston Scientific to Acquire Bolt Medical, Strengthening its Cardiovascular Portfolio

Shots:

  • Boston Scientific has agreed to acquire Bolt Medical, strengthening its cardiovascular portfolio with the addition of Bolt IVL system for coronary & peripheral disease. Deal is expected to close in H1’25
  • Boston, an investor with a 26% equity stake in Bolt Medical, is acquiring the rest 74% for $443M upfront & up to $221M regulatory milestones. (Deal is valued at $600M upfront & up to $300M milestones if the acquisition was for 100% stake)
  • The Bolt IVL System uses lithotripsy to remove calcium in calcified lesions. The pivotal (RESTORE ATK & BTK) studies of Bolt IVL ATK & BTK Systems for PAD are completed, with data supporting the FDA’s approval & CE mark; another global FRACTURE IDE trial of Bolt IVL Coronary System for CAD has begun in Dec 2024

Ref: Boston Scientific | Image: Bolt Medical

Related News:- Boston Scientific Reports the Acquisition of Silk Road Medical

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Tags:
Share Post

You May Also Like

Eli Lilly Partners & Creyon Bio
April 30, 2025
Eli Lilly Partners with Creyon Bio for Accelerated Discovery and Development of RNA-Targeted Oligonucleotides for Various Diseases
Ardelyx 
February 27, 2025
Ardelyx Reports China’s NMPA Approval of Tenapanor for Hyperphosphatemia in Patients
Regeneron
April 18, 2025
The US FDA Accepts sBLA Priority Review for Regeneron’s EYLEA HD in Macular Edema Following RVO and Monthly Dosing In Approved Indications

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]